Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease.

about

Economic evaluations of fluticasone-propionate/salmeterol combination therapy for chronic obstructive pulmonary disease: a review of published studies.Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease.

P2860

Q38721028-034B3D95-9F43-4A45-A1D5-294E6E15CB27 Q49205727-64E6AFD5-BBDD-4097-BFD4-335592144D95

P2860

Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease.

Item

http://www.wikidata.org/entity/Q38125210

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Evaluation of salmeterol xinaf ...... obstructive pulmonary disease.

@en

type

Item

label

Evaluation of salmeterol xinaf ...... obstructive pulmonary disease.

@en

prefLabel

Evaluation of salmeterol xinaf ...... obstructive pulmonary disease.

@en

P1476

Evaluation of salmeterol xinaf ...... obstructive pulmonary disease.

@en

P2093

Andrew Tate

http://www.w3.org/2001/XMLSchema#string

Joshua Coquat

http://www.w3.org/2001/XMLSchema#string

Ruben D Restrepo

http://www.w3.org/2001/XMLSchema#string

P2860

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis.

Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy.

Impact of preventing exacerbations on deterioration of health status in COPD.

Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Relationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4⁺CD25⁺Foxp3⁺ regulatory T cells in COPD.

P304

1993-2002

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2013.823949

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23898819

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease

Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease.

about

P2860

P2860

Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921